Treatment of severe bleeds with eptacog beta in hemophilia A or B with inhibitors: a post hoc analysis of the PERSEPT 1 and 2 trials

Treatment of severe bleeds with eptacog beta in hemophilia A or B with inhibitors: a post hoc analysis of the PERSEPT 1 and 2 trials

Abstract: Severe bleeding episodes (BEs) in persons with hemophilia A or B and inhibitors (PwHABIs) represent challenging clinical situations and can require treatment regimens lasting days or weeks before hemostatic control is achieved. Eptacog beta is a recombinant activated human factor VII bypas...

Full description

Saved in:
Bibliographic Details
Main Authors: Guy Young, Johnny Mahlangu, Lisa N. Boggio, Manuel Carcao, Yesim Dargaud, Miguel Escobar, Adam Giermasz, Cédric Hermans, Philip Kuriakose, Wolfgang Miesbach, Danielle Nance, Amina Rafique, Robert F. Sidonio, Jr., Kateryna V. Vilchevska, Michael Wang, Steven W. Pipe
Format: Article
Language:English
Published: Elsevier 2025-08-01
Series:Blood Vessels, Thrombosis & Hemostasis
Online Access:http://www.sciencedirect.com/science/article/pii/S2950327225000269
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

http://www.sciencedirect.com/science/article/pii/S2950327225000269

Similar Items